Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS.

Cancer Res. 2013 Jan 15;73(2):792-803. doi: 10.1158/0008-5472.CAN-12-1888. Epub 2012 Nov 14.

2.

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, Jacob A.

Neuro Oncol. 2011 Sep;13(9):983-99. doi: 10.1093/neuonc/nor072. Epub 2011 Jul 21.

3.

Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.

Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB, Chang LS.

Otol Neurotol. 2013 Oct;34(8):1519-27. doi: 10.1097/MAO.0b013e3182956169.

4.

Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.

Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M.

Brain Pathol. 2008 Jan;18(1):62-70. Epub 2007 Oct 9.

5.

Group I Paks as therapeutic targets in NF2-deficient meningioma.

Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ, Chernoff J.

Oncotarget. 2015 Feb 10;6(4):1981-94.

6.

Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.

James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF.

Neurobiol Dis. 2008 Feb;29(2):278-92. Epub 2007 Sep 19.

7.

Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.

Simon M, Park TW, Köster G, Mahlberg R, Hackenbroch M, Boström J, Löning T, Schramm J.

J Neurooncol. 2001 Dec;55(3):149-58.

PMID:
11859969
8.

Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.

Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, Quentin S, El-Taraya N, Walczak C, Volk A, Niwa-Kawakita M, Karboul N, Giovannini M, Kalamarides M.

Oncogene. 2013 Sep 5;32(36):4264-72. doi: 10.1038/onc.2012.436. Epub 2012 Oct 8.

PMID:
23045274
9.
10.

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.

Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V.

Oncotarget. 2015 Jul 10;6(19):16981-97.

11.

Reduced expression of schwannomin/merlin in human sporadic meningiomas.

Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubić M.

Neurosurgery. 1997 Mar;40(3):578-87.

PMID:
9055299
12.

The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A.

Neoplasia. 2008 Nov;10(11):1204-12.

13.

Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO.

Mol Cell Biol. 2009 Nov;29(21):5923-40. doi: 10.1128/MCB.00332-09. Epub 2009 Aug 24.

14.

mTORC1 inhibitors suppress meningioma growth in mouse models.

Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C.

Clin Cancer Res. 2013 Mar 1;19(5):1180-9. doi: 10.1158/1078-0432.CCR-12-1904. Epub 2013 Feb 13.

15.

Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.

Dickinson PJ, Surace EI, Cambell M, Higgins RJ, Leutenegger CM, Bollen AW, LeCouteur RA, Gutmann DH.

Vet Pathol. 2009 Sep;46(5):884-92. doi: 10.1354/vp.08-VP-0251-D-FL. Epub 2009 May 9.

16.

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Boström J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP, Reifenberger G.

Am J Pathol. 2001 Aug;159(2):661-9.

17.

NF2 mutations in secretory and other rare variants of meningiomas.

Hartmann C, Sieberns J, Gehlhaar C, Simon M, Paulus W, von Deimling A.

Brain Pathol. 2006 Jan;16(1):15-9.

PMID:
16612978
18.

Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, Giovannini M.

Genes Dev. 2002 May 1;16(9):1060-5.

19.

Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus.

Hansson CM, Buckley PG, Grigelioniene G, Piotrowski A, Hellström AR, Mantripragada K, Jarbo C, Mathiesen T, Dumanski JP.

BMC Genomics. 2007 Jan 12;8:16.

20.

Curcumin acts anti-proliferative and pro-apoptotic in human meningiomas.

Curic S, Wu Y, Shan B, Schaaf C, Utpadel D, Lange M, Kuhlen D, Perone MJ, Arzt E, Stalla GK, Renner U.

J Neurooncol. 2013 Jul;113(3):385-96. doi: 10.1007/s11060-013-1148-9. Epub 2013 May 11.

PMID:
23666203
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk